☆ 4.4 Editorial Material

The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)

Journal

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL

Volume 97, Issue 1, Pages 3-5

Publisher

FERRATA STORTI FOUNDATION

DOI: 10.3324/haematol.2011.057901

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Shukla-Vernon Syndrome: A Second Family with a Novel Variant in the BCORL1 Gene

Babylakshmi Muthusamy, Anikha Bellad, Satish Chandra Girimaji, Akhilesh Pandey

Summary: Shukla-Vernon syndrome is an extremely rare neurodevelopmental disorder caused by pathogenic variants in the BCORL1 gene, characterized by global developmental delay, intellectual disability, and specific dysmorphic facial features.

GENES (2021)

Add to Collection

Editorial Material Cell & Tissue Engineering

SEPHguarding acute myeloid leukemia

Malini Gupta, Britta Will

Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.

CELL STEM CELL (2022)

Add to Collection

Review Immunology

One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia

Zhiding Wang, Jinghong Chen, Mengzhen Wang, Linlin Zhang, Li Yu

Summary: Tim-3 serves as an immune checkpoint in AML, playing a critical role in immune responses and elimination of leukemia stem cells. Its dual functionality as a potential target for curing AML sheds new light on AML immunotherapy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Jan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, Christoph Roellig, Alwin Kraemer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Brummendorf, Ralph Naumann, Bjorn Steffen, Volker Kunzmann, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schafer-Eckart, Christoph Schliemann, Stefan W. Krause, Regina Herbst, Mathias Hanel, Norbert Frickhofen, Richard Noppeney, Ulrich Kaiser, Claudia D. Baldus, Martin Kaufmann, Zdenek Racil, Uwe Platzbecker, Wolfgang E. Berdel, Jiri Mayer, Hubert Serve, Carsten Mueller-Tidow, Gerhard Ehninger, Friedrich Stolzel, Frank Kroschinsky, Johannes Schetelig, Martin Bornhaeuser, Christian Thiede, Jan Moritz Middeke

Summary: The study identified a novel role for loss-of-function mutations of BCOR in AML, indicating their potential impact on risk stratification and treatment allocation.

CANCERS (2021)

Add to Collection

Article Oncology

Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target

Noa G. Holtzman, Michael S. Lebowitz, Rima Koka, Maria R. Baer, Kanam Malhotra, Amir Shahlaee, Hossein A. Ghanbari, Soren M. Bentzen, Ashkan Emadi

Summary: ASPH is expressed on blasts in approximately 40% of AML cases, and may serve as a new therapeutically targetable leukemia-associated antigen.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches

Natasa Tosic, Irena Marjanovic, Jelena Lazic

Summary: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that accounts for 20% of pediatric leukemia cases. While overall survival rates have improved, AML remains a leading cause of mortality in pediatric cancers. Targeted therapy approaches and advances in genomic techniques have identified novel therapeutic targets and provided potential for significant clinical benefits in pediatric AML.

BIOCHEMICAL PHARMACOLOGY (2023)

Add to Collection

Article Immunology

Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia

Roberto Limongello, Andrea Marra, Antonella Mancusi, Samanta Bonato, Eni Hoxha, Loredana Ruggeri, Susanta Hui, Andrea Velardi, Antonio Pierini

Summary: Adverse genetic risk acute myeloid leukemia (AML) poses a significant treatment challenge with poor outcomes, necessitating novel therapeutic approaches. While allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the curative option, high relapse rates and dismal outcomes prompt the exploration of new transplant strategies. Recent research has shown that haploidentical allo-HSCT combined with T cell adoptive immunotherapy can overcome chemoresistance and improve survival in AML patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Hematology

A novel NUP98-JADE2 fusion in a patient with acute myeloid leukemia resembling acute promyelocytic leukemia

Chi-Keung Cheng, Hoi-Yun Chan, Yuk-Lin Yung, Thomas S. K. Wan, Alex W. K. Leung, Chi-Kong Li, Ke Tian, Natalie P. H. Chan, Joyce S. Cheung, Margaret H. L. Ng

Summary: In this study, a NUP98-JADE2 fusion was identified in a pediatric AML patient showing APL-like features. The fusion was found to impair ATRA-mediated transcriptional control and myeloid differentiation. Additionally, the fusion altered the subcellular distribution of JADE2, leading to attenuated ATRA-induced responses and myeloid activation. This is the first report of a NUP98-non-RAR rearrangement in a case resembling APL, indicating the involvement of JADE2 in retinoic acid-induced differentiation.

BLOOD ADVANCES (2022)

Add to Collection

Article Oncology

Identification of two novel mutations in human acute myeloid leukemia cases

Grainne O'Brien, Joanna Zyla, Kalliopi N. Manola, Maria N. Pagoni, Joanna Polanska, Christophe Badie

Summary: AML is an aggressive cancer with rapid progression, where cytogenetic and genetic analysis play crucial roles in diagnosis and prognosis. This study identified two novel deleterious mutations in DNMT3A and RUNX1 genes, providing additional information for patient diagnosis and prognosis. The exclusion and co-occurrence of specific gene mutation patterns in AML were also confirmed, offering insights into the mechanisms of AML leukaemogenesis.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Checkpoint Inhibitors in Acute Myeloid Leukemia

Daniela Damiani, Mario Tiribelli

Summary: The prognosis of acute myeloid leukemia (AML) is poor due to tumor cell immune escape, which weakens T-cells. Inhibiting immune checkpoints (ICs) through immune checkpoint inhibitors (ICIs) has emerged as a promising therapeutic strategy for AML. However, the results of clinical trials testing ICIs, alone or in combination with other treatments, in AML are conflicting.

BIOMEDICINES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Circular RNAs in acute myeloid leukemia

Vijendra Singh, Mohammed Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian

Summary: While mechanistic studies have shed light on the molecular mechanisms of AML and led to the development of new targeted therapies, resistance remains a significant issue in AML treatment. The exploration of circRNA in AML biology and therapy resistance shows promise in providing new insights and potential solutions to managing this disease.

MOLECULAR CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Emerging Immunotherapy for Acute Myeloid Leukemia

Rikako Tabata, SungGi Chi, Junichiro Yuda, Yosuke Minami

Summary: Studies have suggested the potential clinical benefits of immuno-oncology therapy against AML, including immune checkpoint inhibitors and bi-/tri-specific antibodies. CAR-T and NK cells have shown effectiveness for relapsed/refractory AML patients, and conventional chemotherapy combined with anti-PD-1/anti-CTLA4 antibodies also demonstrated certain efficacy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Pediatrics

BCORL1 S878G, GNB1 G116S, SH2B3 A536T, and KMT2D S3708R tetramutation co-contribute to a pediatric acute myeloid leukemia: Case report and literature review

Liang Wang, Sen Chen, Yongming Shen, Ping Si

Summary: This study reports the genetic alterations in a pediatric patient with acute myeloid leukemia (AML), including mutations in BCORL1, GNB1, SH2B3, and KMT2D. The concurrence of these mutations may contribute to disease progression. The patient eventually died of respiratory failure.

FRONTIERS IN PEDIATRICS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Identification of the Thyrotropin-Releasing Hormone (TRH) as a Novel Biomarker in the Prognosis for Acute Myeloid Leukemia

Yan Gao, Jia-Fan Zhou, Jia-Ying Mao, Lu Jiang, Xue-Ping Li

Summary: Using single-cell RNA sequencing technology, the study revealed the prognostic value of thyrotropin-releasing hormone (TRH) as a biomarker in RUNX1-RUNX1T1 AML. TRH expression was found to be associated with age and genetic mutations, and it could improve the risk stratification system in AML.

BIOMOLECULES (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of a novel oral type I CDK8 inhibitor against acute myeloid leukemia

Xing Xing Zhang, Yao Yao Yan, Xiao Ma, Yun Xiao, Cen Cen Lei, Yu Meng Wang, Chao Liu, Quan Wang, Xing Tao Zhang, Wen Dan Cheng, Xin Hua Liu

Summary: CDK8, a key player in acute myeloid leukemia and colorectal cancer, was targeted using a novel compound 43. The compound demonstrated strong inhibitory activity against CDK8, good selectivity, and anti-proliferative effects on AML cells. Mechanistic studies revealed that compound 43 directly targeted CDK8, leading to the inhibition of AML cell proliferation through phosphorylation of STAT-1 and STAT-5. In addition, compound 43 showed good bioavailability and dose-dependent inhibition of AML tumor growth in vivo. This study contributes to the development of more potent CDK8 inhibitors for AML treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Add to Collection

Article Oncology

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML

Ilaria Gionfriddo, Lorenzo Brunetti, Federica Mezzasoma, Francesca Milano, Valeria Cardinali, Roberta Ranieri, Alessandra Venanzi, Sara Pierangeli, Calogero Vetro, Giulio Spinozzi, Erica Dorillo, Hsin Chieh Wu, Caroline Berthier, Raffaella Ciurnelli, Melanie J. Griffin, Claire E. Jennings, Enrico Tiacci, Paolo Sportoletti, Franca Falzetti, Hugues de The, Gareth J. Veal, Maria Paola Martelli, Brunangelo Falini

Summary: Relapsed or refractory AML patients with NPM1 mutations face challenges in treatment, particularly in elderly and unfit individuals. Dactinomycin, a low-cost chemotherapeutic agent, shows potential as an alternative treatment option, possibly through its association with nucleolar stress. Further investigation in larger clinical studies is warranted.

LEUKEMIA (2021)

Add to Collection

Article Oncology

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells

Vincenzo Maria Perriello, Ilaria Gionfriddo, Roberta Rossi, Francesca Milano, Federica Mezzasoma, Andrea Marra, Orietta Spinelli, Alessandro Rambaldi, Ombretta Annibali, Giuseppe Avvisati, Francesco Di Raimondo, Stefano Ascani, Brunangelo Falini, Maria Paola Martelli, Lorenzo Brunetti

Summary: One-third of adult AML patients have NPM1 mutations, with high expression of CD123 identified as a potential target for therapy in NPM1-mutated leukemic cells, particularly in CD34(+)CD38(-) cells. Targeting CD123 may be effective for treating NPM1-mutated AML, especially in combination with FLT3 mutations.

CANCERS (2021)

Add to Collection

Article Hematology

Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia

Antonio Pierini, Loredana Ruggeri, Alessandra Carotti, Franca Falzetti, Simonetta Saldi, Adelmo Terenzi, Claudio Zucchetti, Gianluca Ingrosso, Tiziana Zei, Roberta Iacucci Ostini, Sara Piccinelli, Samanta Bonato, Sara Tricarico, Antonella Mancusi, Sara Ciardelli, Roberto Limongello, Mara Merluzzi, Mauro Di Ianni, Rita Tognellini, Olivia Minelli, Cristina Mecucci, Maria Paola Martelli, Brunangelo Falini, Massimo Fabrizio Martelli, Cynthia Aristei, Andrea Velardi

Summary: A novel HLA-haploidentical HSCT strategy, combining an age-adapted myeloablative conditioning regimen with regulatory and conventional T-cell adoptive immunotherapy, resulted in a significant improvement in cGVHD/relapse-free survival rate in 50 AML patients.

BLOOD ADVANCES (2021)

Add to Collection

Article Oncology

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field

Brunangelo Falini, Sofia Sciabolacci, Lorenza Falini, Lorenzo Brunetti, Maria Paola Martelli

Summary: Mutations of Nucleophosmin (NPM1) are common in adult AML and are recognized as a distinct entity. Evaluation of NPM1 and FLT3 status is important for risk stratification and monitoring of MRD. Combining MRD monitoring with the ELN prognostication model can help guide therapeutic decisions for NPM1-mutated AML.

LEUKEMIA (2021)

Add to Collection

Review Oncology

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Claudio Cerchione, Alessandra Romano, Naval Daver, Courtney DiNardo, Elias Joseph Jabbour, Marina Konopleva, Farhad Ravandi-Kashani, Tapan Kadia, Maria Paola Martelli, Alessandro Isidori, Giovanni Martinelli, Hagop Kantarjian

Summary: The discovery of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2 has led to the development of individualized treatment strategy in approximately 20% of patients with acute myeloid leukemia (AML). Targeting IDH to promote differentiation and maturation of malignant clone is an emerging strategy in AML, and small molecule inhibitors have shown promising efficacy in phase I/II trials. The contribution of IDH1/IDH2 mutations in leukemogenesis and progress of targeted therapeutics in AML is highlighted in this review.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

Monica Messina, Alfonso Piciocchi, Tiziana Ottone, Stefania Paolini, Cristina Papayannidis, Federica Lessi, Nicola Stefano Fracchiolla, Fabio Forghieri, Anna Candoni, Andrea Mengarelli, Maria Paola Martelli, Adriano Venditti, Angelo Michele Carella, Francesco Albano, Valentina Mancini, Bernardi Massimo, Valentina Arena, Valeria Sargentini, Mariarita Sciume, Domenico Pastore, Elisabetta Todisco, Giovanni Roti, Sergio Siragusa, Marco Ladetto, Stefano Pravato, Eleonora De Bellis, Giorgia Simonetti, Giovanni Marconi, Claudio Cerchione, Paola Fazi, Marco Vignetti, Sergio Amadori, Giovanni Martinelli, Maria Teresa Voso

Summary: IDH1/2 mutations are common in acute myeloid leukemia (AML) and represent a therapeutic target. The GIMEMA AML1516 observational protocol confirms that IDH1/2 mutations are frequently detected at diagnosis and emphasizes the importance of recognizing IDH1/2-mutated cases up-front to offer the most appropriate therapeutic strategy, given the availability of IDH1/2 inhibitors. In the subset of IDH1/2-mutated patients, complete remission achievement rate and overall survival at 2 years were similar to IDH1/2-WT patients.

CANCERS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

SiCoDEA: A Simple, Fast and Complete App for Analyzing the Effect of Individual Drugs and Their Combinations

Giulio Spinozzi, Valentina Tini, Alessio Ferrari, Ilaria Gionfriddo, Roberta Ranieri, Francesca Milano, Sara Pierangeli, Serena Donnini, Federica Mezzasoma, Serenella Silvestri, Brunangelo Falini, Maria Paola Martelli

Summary: Drug combination administration is widely used for the treatment of various pathologies. The importance lies in studying the synergy, antagonism, or additivity of specific combinations. SiCoDEA is an easy-to-use tool for analyzing drug combination data with various models.

BIOMOLECULES (2022)

Add to Collection

Article Pharmacology & Pharmacy

From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia

Andrea Astolfi, Francesca Milano, Deborah Palazzotti, Jose Brea, Maria Chiara Pismataro, Mariangela Morlando, Oriana Tabarrini, Maria Isabel Loza, Serena Massari, Maria Paola Martelli, Maria Letizia Barreca

Summary: This study aims to find novel anti-leukemia drugs. The compound T126 has been identified as a potent AKT1 inhibitor, showing significant effects on growth inhibition and induction of apoptosis in AML cells. This lays the foundation for future development of new AKT1 inhibitors as therapeutic drugs for leukemia.

PHARMACEUTICS (2022)

Add to Collection

Article Hematology

Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia

Brunangelo Falini, Maria Paola Martelli

Summary: The WHO classification of lympho-hemopoietic neoplasms in 2001, 2008, and 2016 has served as the international standard for diagnosis, but significant advancements have been made in myeloid neoplasms since the 4th WHO edition. This has led to the development of the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO-HAEM5). This paper reviews and compares these two classifications, focusing on adult myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML), with the aim of providing a useful tool for pathologists, hematologists, and researchers involved in the diagnosis and treatment of these hematological malignancies.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Editorial Material Hematology

Mutant NPM1: Nuclear export and the mechanism of leukemogenesis

Brunangelo Falini, Maria Paola Martelli, Lorenzo Brunetti

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Editorial Material Hematology

Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia-aCML)

Giovanni Martino, Martina Quintini, Maria Paola Martelli, Stefano Ascani, Stefano Lazzi, Cristina Mecucci

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Letter Hematology

The NPM1 mutant defines AML irrespective of blast count

Brunangelo Falini, Maria Paola Martelli, Lorenzo Brunetti, Bjorn T. Gjertsen, Vibeke Andresen

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation

Antonella Mancusi, Francesco Zorutti, Loredana Ruggeri, Samanta Bonato, Sara Tricarico, Tiziana Zei, Roberta Iacucci Ostini, Valerio Viglione, Rebecca Sembenico, Sofia Sciabolacci, Valeria Cardinali, Massimo Fabrizio Martelli, Cristina Mecucci, Alessandra Carotti, Maria Paola Martelli, Andrea Velardi, Antonio Pierini

Summary: This study demonstrates the feasibility of using blinatumomab and DLI to treat relapses after Treg/Tcon haploidentical HSCT, and suggests that their preemptive use could improve efficacy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Hematology

How I diagnose and treat NPM1-mutated AML

Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli

Summary: Mutations of the nucleophosmin (NPM1) gene play a crucial role in adult acute myeloid leukemia (AML), with unique molecular, pathological, and clinical features. Accurate diagnosis and distinction of NPM1-mutated AML from other entities is important for guiding treatment decisions and assessing relapse risk. Monitoring measurable residual disease (MRD) using NPM1 mutations can provide valuable insights for therapeutic management after remission.

BLOOD (2021)

Add to Collection

Article Oncology

Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice

Paolo Sportoletti, Daniele Sorcini, Anna G. Guzman, Jaime M. Reyes, Arianna Stella, Andrea Marra, Sara Sartori, Lorenzo Brunetti, Roberta Rossi, Beatrice Del Papa, Francesco Maria Adamo, Giulia Pianigiani, Camilla Betti, Annarita Scialdone, Valerio Guarente, Giulio Spinozzi, Valentina Tini, Maria Paola Martelli, Margaret A. Goodell, Brunangelo Falini

Summary: Recurrent loss-of-function mutations of the BCOR gene are associated with poor prognosis in AML patients, leading to the creation of a mouse model to study this AML genotype. Double knockout mice showed features of acute erythroid leukemia, suggesting potential efficacy of demethylating agents in AEL treatment.

LEUKEMIA (2021)

Add to Collection

No Data Available

The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia

Journal

Publisher

FERRATA STORTI FOUNDATION

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper